FILGRASTIM
Hematologic Malignancy
St. Jude Children's Research Hospitalprotein_peptidePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 73/ 100
Competitive context
42 Active assets in the Hematologic Malignancy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine National Cancer Institute (NCI) | Phase 3 | BB |
Cyclophosphamide National Cancer Institute (NCI) | Phase 2 | B |
Cytosin-Arabinosid Senti Biosciences | Phase 2 | B |
Venetoclax University of Alabama at Birmingham | Phase 2 | B |
Azacitidine Therapeutic Advances in Childhood Leukemia Consortium | Phase 2 | B |
View all 50 →
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →